Wall Street Analysts Are Neutral on Top Healthcare Picks
Analysts fell to the sidelines weighing in on Moderna (MRNA – Research Report) and Teladoc (TDOC – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Moderna (MRNA)
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Moderna on February 23 and set a price target of $30.00. The company’s shares closed last Wednesday at $51.37, close to its 52-week low of $29.25.
According to TipRanks.com, Flynn is a 5-star analyst with an average return of
Currently, the analyst consensus on Moderna is a Hold with an average price target of $36.13, representing a -28.8% downside. In a report issued on February 11, Jefferies also maintained a Hold rating on the stock with a $30.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Teladoc (TDOC)
Needham analyst Ryan MacDonald reiterated a Hold rating on Teladoc today. The company’s shares closed last Wednesday at $4.65.
According to TipRanks.com, MacDonald is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Teladoc has an analyst consensus of Hold, with a price target consensus of $7.56, implying a 63.6% upside from current levels. In a report issued on February 18, BTIG also maintained a Hold rating on the stock.
